ZBH

Business Context and Reporting Period

Company: Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.)
Reporting Period: Fiscal Year Ended December 31, 2003
Business Overview: A global leader in reconstructive orthopaedic implants (joint, dental, spinal), trauma products, and surgical supplies. Operations are managed across three geographic segments: Americas, Europe, and Asia Pacific.
Key Event: On October 2, 2003, the Company closed the acquisition of Centerpulse AG and InCentive Capital AG for approximately $3.4 billion ($2.2 billion in stock, $1.2 billion in cash). This acquisition significantly expanded Zimmer's presence in the European market and added spinal and dental implant capabilities.

Key Financial Metrics

Note: 2003 results include Centerpulse operations from October 2, 2003. Net earnings include a one-time, non-cash cumulative effect of a change in accounting principle of $55.1 million (net of tax).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 39% to $1.901 billion. This comprised a 20% increase in "Zimmer standalone" sales and a 19% increase attributable to the Centerpulse acquisition.
• Profitability: Net earnings rose 34% to $346.3 million. Operating profit increased 12% to $450.7 million.
• Margin Compression: Gross margin decreased from 74.9% to 72.8%. This was primarily due to a $42.7 million inventory step-up charge related to the Centerpulse acquisition and the inclusion of Centerpulse's lower-margin European sales mix.
• Debt Structure: Total debt surged from $156.7 million to $1.109 billion to finance the Centerpulse acquisition. The Company established a new $1.75 billion Senior Credit Facility.
• Accounting Change: Effective January 1, 2003, the Company changed its accounting for surgical instruments from expensing to capitalizing as long-lived assets. This change favorably impacted operating profit by $26.8 million and resulted in a $55.1 million cumulative effect adjustment to net earnings.

Guidance, Outlook, and Risks

• Integration Costs: The Company recorded $79.6 million in acquisition and integration costs in 2003 and expects to incur an additional $128.0 million in 2004.
• Sales Dis-synergies: Management expects approximately $50 million in sales dis-synergies in 2004 due to integration challenges, particularly in European markets (France, Italy, Germany).
• R&D Investment: The Company plans to maintain R&D spending at approximately 6% of sales to support investments in spine, biologics, and new technologies.
• Future Acquisitions: On March 2, 2004, the Company entered into an agreement to acquire Implex Corp. for approximately $108 million (initial cash payment) plus contingent earn-outs.
• Risks and Contingencies:
  • SEC Investigation: The SEC is conducting an informal investigation into Centerpulse AG regarding certain accounting issues.
  • Litigation: The Company faces product liability claims related to Centerpulse's hip and knee implants (voluntary recall) and a patent infringement lawsuit filed by BTG International Limited regarding the Trilogy Acetabular System.
  • Regulatory: Pricing pressure in Japan (expected 4-6% decline in mid-to-late 2004) and potential changes in reimbursement programs globally.

Investor Verification Checklist

• Integration Progress: Verify the timeline and cost management of the Centerpulse integration, specifically the projected $128 million in 2004 expenses.
• European Performance: Monitor sales trends in Europe to confirm if the anticipated $50 million dis-synergy materializes and if market share stabilizes.
• Debt Servicing: Assess the Company's ability to service the new $1.1 billion debt load using operating cash flows, noting the target to pay off remaining debt by end of 2006.
• Legal Outcomes: Track the resolution of the SEC investigation into Centerpulse and the BTG patent infringement lawsuit.
• Implex Acquisition: Confirm the closing of the Implex Corp. acquisition and the valuation of contingent earn-out payments.